Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Recruiting No phase listed Observational

BostonGene and Exigent Genomic INsight Study

ClinicalTrials.gov ID: NCT06272864

Public ClinicalTrials.gov record NCT06272864. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 3, 2026, 8:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

BostonGene and Exigent Genomic INsight (BEGIN) Study: A Prospective Study of Comprehensive Molecular Testing in Advanced Cancer Patients in the Community Setting

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The BEGIN Study by BostonGene and Exigent Genomic INsight evaluates the efficacy of comprehensive molecular testing in advanced cancer patients. Using the BostonGene Tumor Portrait test, the study aims to identify actionable findings, assess feasibility, and determine patient enrollment in clinical trials. Four cohorts of 100 patients each will be studied over two years, focusing on treatment decisions and patient outcomes. This study seeks to demonstrate the clinical utility of genomic testing in guiding therapy for advanced cancer patients in community settings.

Study identification

NCT ID
NCT06272864
Recruitment status
Recruiting
Study type
Observational
Phase
Not listed
Lead sponsor
BostonGene
Industry
Enrollment
400 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 7, 2024
Primary completion
Jan 7, 2026
Completion
Jan 7, 2028
Last update posted
Feb 16, 2025

2024 – 2028

United States locations

U.S. sites
7
U.S. states
7
U.S. cities
7
Facility City State ZIP Site status
Highlands Oncology Group Rogers Arkansas 72758 Recruiting
Stockton Hematology Oncology Medical Group Stockton California 95204 Recruiting
Fort Wayne Medical Oncology and Hematology Fort Wayne Indiana 46804 Recruiting
New Mexico Cancer Center Albuquerque New Mexico 87109 Recruiting
Oklahoma Cancer Specialists and Research Institute Tulsa Oklahoma 74146 Recruiting
Oncology Consultants Houston Texas 77030 Recruiting
Northwest Medical Specialities Puyallup Washington 98373 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06272864, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 16, 2025 · Synced Sep 3, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06272864 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →